497 related articles for article (PubMed ID: 18076132)
1. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
2. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
Tabotta W; Klein D; Hohenadl C; Salmons B; Günzburg WH
J Gene Med; 2001; 3(5):418-26. PubMed ID: 11601755
[TBL] [Abstract][Full Text] [Related]
3. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
4. Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors.
Ketteler R; Glaser S; Sandra O; Martens UM; Klingmüller U
Gene Ther; 2002 Apr; 9(8):477-87. PubMed ID: 11948372
[TBL] [Abstract][Full Text] [Related]
5. WPRE-mediated enhancement of gene expression is promoter and cell line specific.
Klein R; Ruttkowski B; Knapp E; Salmons B; Günzburg WH; Hohenadl C
Gene; 2006 May; 372():153-61. PubMed ID: 16488559
[TBL] [Abstract][Full Text] [Related]
6. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors.
Hlavaty J; Schittmayer M; Stracke A; Jandl G; Knapp E; Felber BK; Salmons B; Günzburg WH; Renner M
Virology; 2005 Oct; 341(1):1-11. PubMed ID: 16054668
[TBL] [Abstract][Full Text] [Related]
7. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
[TBL] [Abstract][Full Text] [Related]
8. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.
Higashimoto T; Urbinati F; Perumbeti A; Jiang G; Zarzuela A; Chang LJ; Kohn DB; Malik P
Gene Ther; 2007 Sep; 14(17):1298-304. PubMed ID: 17597793
[TBL] [Abstract][Full Text] [Related]
9. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors.
Freas-Lutz DL; Correll PH; Dougherty SF; Xu L; Pluznik DH; Karlsson S
Exp Hematol; 1994 Aug; 22(9):857-65. PubMed ID: 8062885
[TBL] [Abstract][Full Text] [Related]
10. Retroviral vector backbone immunogenicity: identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences.
Kondo E; Akatsuka Y; Nawa A; Kuzushima K; Tsujimura K; Tanimoto M; Kodera Y; Morishima Y; Kuzuya K; Takahashi T
Gene Ther; 2005 Feb; 12(3):252-8. PubMed ID: 15496958
[TBL] [Abstract][Full Text] [Related]
11. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression.
Schambach A; Bohne J; Baum C; Hermann FG; Egerer L; von Laer D; Giroglou T
Gene Ther; 2006 Apr; 13(7):641-5. PubMed ID: 16355114
[TBL] [Abstract][Full Text] [Related]
12. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo.
Mavria G; Jäger U; Porter CD
Gene Ther; 2000 Mar; 7(5):368-76. PubMed ID: 10694818
[TBL] [Abstract][Full Text] [Related]
13. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
14. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
15. Self-inactivating retroviral vectors with improved RNA processing.
Kraunus J; Schaumann DH; Meyer J; Modlich U; Fehse B; Brandenburg G; von Laer D; Klump H; Schambach A; Bohne J; Baum C
Gene Ther; 2004 Nov; 11(21):1568-78. PubMed ID: 15372067
[TBL] [Abstract][Full Text] [Related]
16. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
[TBL] [Abstract][Full Text] [Related]
17. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter.
Shi CX; Graham FL; Hitt MM
J Gene Med; 2006 Apr; 8(4):442-51. PubMed ID: 16389604
[TBL] [Abstract][Full Text] [Related]
18. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
Shi CX; Long MA; Liu L; Graham FL; Gauldie J; Hitt MM
Mol Ther; 2004 Oct; 10(4):758-67. PubMed ID: 15451460
[TBL] [Abstract][Full Text] [Related]
19. Development of murine leukemia virus-based retroviral vectors with a minimum possibility of cis-activation.
Jang J; Lee JT; Lee K; Kim S; Kim JY; Yoon K; Kim S
Gene Ther; 2011 Mar; 18(3):240-9. PubMed ID: 20944681
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vector targeting for gene therapy.
Günzburg WH; Fleuchaus A; Saller R; Salmons B
Cytokines Mol Ther; 1996 Sep; 2(3):177-84. PubMed ID: 9384702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
